Company intelligence / Profile preview

Hinoman

Tel Aviv, Tel Aviv, Israelhinoman.com ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Hinoman has commercialized its core ingredient, Mankai, a proprietary, hydroponically grown, whole-plant protein source with high nutritional value used for food ingredient and whole vegetable applications. No clinical trial results are reported; efficacy and benefits pertain to nutritional utility.

Industry: Food & Nutrition

Drug pipeline

1 asset

Mankai

Commercial

Indications: Nutrition, Blood glucose control, Iron deficiency, Cardiometabolic health

Partnerships

Ajinomoto

Beyond the preview

Go deeper on Hinoman.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hinoman.

Explore the full profile